Your browser doesn't support javascript.
Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland.
McGurnaghan, Stuart J; Weir, Amanda; Bishop, Jen; Kennedy, Sharon; Blackbourn, Luke A K; McAllister, David A; Hutchinson, Sharon; Caparrotta, Thomas M; Mellor, Joseph; Jeyam, Anita; O'Reilly, Joseph E; Wild, Sarah H; Hatam, Sara; Höhn, Andreas; Colombo, Marco; Robertson, Chris; Lone, Nazir; Murray, Janet; Butterly, Elaine; Petrie, John; Kennon, Brian; McCrimmon, Rory; Lindsay, Robert; Pearson, Ewan; Sattar, Naveed; McKnight, John; Philip, Sam; Collier, Andrew; McMenamin, Jim; Smith-Palmer, Alison; Goldberg, David; McKeigue, Paul M; Colhoun, Helen M.
  • McGurnaghan SJ; Health Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK; Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
  • Weir A; Health Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
  • Bishop J; Health Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
  • Kennedy S; Health Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
  • Blackbourn LAK; Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
  • McAllister DA; Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
  • Hutchinson S; School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.
  • Caparrotta TM; Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
  • Mellor J; Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
  • Jeyam A; Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
  • O'Reilly JE; Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
  • Wild SH; Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
  • Hatam S; Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
  • Höhn A; Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
  • Colombo M; Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
  • Robertson C; Health Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK; Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK.
  • Lone N; Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
  • Murray J; Health Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
  • Butterly E; Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
  • Petrie J; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
  • Kennon B; Queen Elizabeth University Hospital, Glasgow, UK.
  • McCrimmon R; University of Dundee, Dundee, UK.
  • Lindsay R; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
  • Pearson E; University of Dundee, Dundee, UK.
  • Sattar N; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
  • McKnight J; Western General Hospital, National Health Service Lothian Edinburgh, UK.
  • Philip S; Grampian Diabetes Research Unit, Diabetes Centre, Aberdeen Royal Infirmary, Aberdeen, UK.
  • Collier A; School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.
  • McMenamin J; Health Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
  • Smith-Palmer A; Health Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
  • Goldberg D; Health Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
  • McKeigue PM; Health Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK; Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
  • Colhoun HM; Health Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK; Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK; Department of Public Health, National Health Service Fif
Lancet Diabetes Endocrinol ; 9(2): 82-93, 2021 02.
Article in English | MEDLINE | ID: covidwho-989524
ABSTRACT

BACKGROUND:

We aimed to ascertain the cumulative risk of fatal or critical care unit-treated COVID-19 in people with diabetes and compare it with that of people without diabetes, and to investigate risk factors for and build a cross-validated predictive model of fatal or critical care unit-treated COVID-19 among people with diabetes.

METHODS:

In this cohort study, we captured the data encompassing the first wave of the pandemic in Scotland, from March 1, 2020, when the first case was identified, to July 31, 2020, when infection rates had dropped sufficiently that shielding measures were officially terminated. The participants were the total population of Scotland, including all people with diabetes who were alive 3 weeks before the start of the pandemic in Scotland (estimated Feb 7, 2020). We ascertained how many people developed fatal or critical care unit-treated COVID-19 in this period from the Electronic Communication of Surveillance in Scotland database (on virology), the RAPID database of daily hospitalisations, the Scottish Morbidity Records-01 of hospital discharges, the National Records of Scotland death registrations data, and the Scottish Intensive Care Society and Audit Group database (on critical care). Among people with fatal or critical care unit-treated COVID-19, diabetes status was ascertained by linkage to the national diabetes register, Scottish Care Information Diabetes. We compared the cumulative incidence of fatal or critical care unit-treated COVID-19 in people with and without diabetes using logistic regression. For people with diabetes, we obtained data on potential risk factors for fatal or critical care unit-treated COVID-19 from the national diabetes register and other linked health administrative databases. We tested the association of these factors with fatal or critical care unit-treated COVID-19 in people with diabetes, and constructed a prediction model using stepwise regression and 20-fold cross-validation.

FINDINGS:

Of the total Scottish population on March 1, 2020 (n=5 463 300), the population with diabetes was 319 349 (5·8%), 1082 (0·3%) of whom developed fatal or critical care unit-treated COVID-19 by July 31, 2020, of whom 972 (89·8%) were aged 60 years or older. In the population without diabetes, 4081 (0·1%) of 5 143 951 people developed fatal or critical care unit-treated COVID-19. As of July 31, the overall odds ratio (OR) for diabetes, adjusted for age and sex, was 1·395 (95% CI 1·304-1·494; p<0·0001, compared with the risk in those without diabetes. The OR was 2·396 (1·815-3·163; p<0·0001) in type 1 diabetes and 1·369 (1·276-1·468; p<0·0001) in type 2 diabetes. Among people with diabetes, adjusted for age, sex, and diabetes duration and type, those who developed fatal or critical care unit-treated COVID-19 were more likely to be male, live in residential care or a more deprived area, have a COVID-19 risk condition, retinopathy, reduced renal function, or worse glycaemic control, have had a diabetic ketoacidosis or hypoglycaemia hospitalisation in the past 5 years, be on more anti-diabetic and other medication (all p<0·0001), and have been a smoker (p=0·0011). The cross-validated predictive model of fatal or critical care unit-treated COVID-19 in people with diabetes had a C-statistic of 0·85 (0·83-0·86).

INTERPRETATION:

Overall risks of fatal or critical care unit-treated COVID-19 were substantially elevated in those with type 1 and type 2 diabetes compared with the background population. The risk of fatal or critical care unit-treated COVID-19, and therefore the need for special protective measures, varies widely among those with diabetes but can be predicted reasonably well using previous clinical history.

FUNDING:

None.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Population Surveillance / Diabetes Mellitus / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Europa Language: English Journal: Lancet Diabetes Endocrinol Year: 2021 Document Type: Article Affiliation country: S2213-8587(20)30405-8

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Population Surveillance / Diabetes Mellitus / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Europa Language: English Journal: Lancet Diabetes Endocrinol Year: 2021 Document Type: Article Affiliation country: S2213-8587(20)30405-8